Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.

View All Information for Patients & Visitors »

New to MyHealth?

Manage Your Care From Anywhere.

Access your health information from any device with MyHealth. You can message your clinic, view lab results, schedule an appointment, and pay your bill.

Activate Your Account with an access code or Create a New Account

MyHealth for Mobile

The MyHealth mobile app puts all your health information at your fingertips and makes managing your health care simple and quick. Available for iPhone and Android.

Ubenimex in Adult Patients with Secondary Lymphedema of the Lower Limb: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Pharmacokinetics (ULTRA) of Ubenimex in Adult Patients with Secondary Lymphedema of the Lower Limb

Trial ID or NCT#

NCT02700529

Status

RECRUITING

Purpose

Leukotriene B4 (LTB4) inhibits lymphangiogenesis in the mouse tail model of lymphedema and is elevated in tissue in patients with lymphedema. Ubenimex is an inhibitor of leukotriene A4 hydrolase (LTA4H), the biosynthetic enzyme for LTB4. This proof-of-concept study is designed as a randomized, double-blind, placebo-controlled study comparing ubenimex at 150 mg, 3 times daily (total daily dose of 450 mg) with placebo for 6 months treatment period in patients with secondary leg lymphedema.

The primary objectives for the study are to evaluate the efficacy, safety and tolerability of ubenimex in patients with secondary leg lymphedema.

Official Title

Ubenimex in Adult Patients With Lymphedema of The Lower Limb: a Phase 2, RAndomized, Double-blind, Placebo-controlled Study of Efficacy, Safety, and Pharmacokinetics (ULTRA)

Eligibility Criteria

Ages Eligible for Study: 18 Years to 75 Years

Sexes Eligible for Study: All

Accepts Healthy Volunteers: No

Inclusion Criteria:

1. Has a diagnosis of secondary leg lymphedema, based on a positive lymphoscintigraphy (LSG) study of the affected leg OR has a diagnosis of primary lymphedema not of congenital onset affecting one or both lower limbs, based on positive LSG.
2. Swelling of at least 1 leg not completely reversed by leg elevation or compression.
3. Stage II or greater lymphedema, based on the International Society of Lymphology (ISL) staging system.
4. Completion of a full course of complete decongestive therapy (CDT).
5. Stable limb volume (within 10% during screening for worse/affected leg) .
6. If patient has had a lymphatic vascularization procedure (lymphovenous bypass or lymph node transfer) or liposuction for lymphedema in the affected limb, then procedure must have been performed at least 1 year (12 months) prior to Screening AND affected limb must be clinically stable over the 3 months prior to Screening AND significant residual disease must be present.
7. Ambulatory status (use of a walking aid is permitted).
8. Agree to use a medically acceptable method of contraception, if the possibility of conception exists.

Exclusion Criteria:

Exclusions Based on Lymphedema:

1. A diagnosis of primary lymphedema with congenital onset. Primary lymphedema is defined as lymphedema with onset prior to or without an inciting event (e.g, surgery, trauma, radiation)
2. Occurrence of significant lymphedema of another body part that is not the lower limb (e.g, upper extremity, trunk, head and neck, genitalia).
3. Lymphedema involving all four limbs
4. Recent initiation of, or intention to initiate CDT or maintenance physiotherapy for lymphedema.

Exclusions Based on Other Medical Conditions

5. Deep venous thrombosis in either lower limb or systemic anticoagulation within 6 months
6. Other medical condition that could lead to acute or chronic leg edema.
7. Other medical condition that could result in symptoms overlapping those of lymphedema in the affected leg.
8. History of clotting disorder (hypercoagulable state).
9. Chronic (persistent) infection in either lower limb.
10. Cellulitis or other infection in either lower limb or use of antibiotics for cellulitis within 3 months prior to screening.
11. Other unstable or severe medical condition requiring active management and/or likely to decompensate/require active management within the next year
12. Current evidence of malignancy.
13. History of malignancy within the previous 3 years, except for nonmelanoma skin cancer or cervical carcinoma in situ treated with curative intent.
14. Currently receiving chemotherapy or radiation therapy.
15. Life expectancy < 2 years for any reason.
16. Pregnancy or nursing.
17. Substance abuse (such as alcohol or drug abuse) within 6 months prior to screening.

Exclusions Based on Concurrent Medication Use

18. Regular concurrent use or regular use within 6 months before screening of another leukotriene pathway inhibitor.
19. Concurrent antibiotic use.
20. Concurrent use of any agent active on the sphingosine-1-phosphate (S1P) pathway.
21. Concurrent use of unapproved (including herbal) treatments for lymphedema.

Exclusions Based on Laboratory Values

22. Significant or chronic renal insufficiency or requires dialytic support.
23. Hepatic dysfunction.
24. Absolute neutrophil count <1500 mm3 at screening.
25. Hemoglobin concentration <9 g/dL at screening.

View All Criteria

Investigator(s)

Stanley G. Rockson, MD

Cardiologist

Allan and Tina Neill Professor of Lymphatic Research and Medicine

CONTACT

Les Roche, RN
(650) 723-1396

SEND MESSAGE

View on ClinicalTrials.gov

New to MyHealth?

MyHealth for Mobile

Ubenimex in Adult Patients with Secondary Lymphedema of the Lower Limb: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Pharmacokinetics (ULTRA) of Ubenimex in Adult Patients with Secondary Lymphedema of the Lower Limb

Trial ID or NCT#

Status

Purpose

Official Title

Eligibility Criteria

Investigator(s)

CONTACT

About this Clinical Trial

Your Message Will Go To

To:

New to MyHealth?

MyHealth for Mobile

WELCOME BACK

Ubenimex in Adult Patients with Secondary Lymphedema of the Lower Limb: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Pharmacokinetics (ULTRA) of Ubenimex in Adult Patients with Secondary Lymphedema of the Lower Limb

Trial ID or NCT#

Status

Purpose

Official Title

Eligibility Criteria

Investigator(s)

CONTACT

About this Clinical Trial

Your Message Will Go To

To: